Prevalence and severity of anxiety, stress, and depression in long COVID among adults in Barcelona

BJGP Open, Journal Year: 2025, Volume and Issue: unknown, P. BJGPO.2024.0098 - BJGPO.2024.0098

Published: Jan. 23, 2025

Background The COVID-19 pandemic’s long-term mental health implications are increasingly concerning, especially among patients suffering post-acute sequelae of SARS-CoV-2 infection: Long COVID (LC) patients. Aim This study explores the presence and distribution anxiety, depression, stress in LC individuals with cognitive complaints northern Barcelona (Spain). Design & settings cross-sectional involved 155 diagnosed from “Aliança ProHEpiC-19 Cognitiu (APC)” project. Method Demographic data behavior variables were collected, Depression, Anxiety, Stress Scale (DASS-21) was self-administered to assess health. Descriptive statistics, chi-squared tests, Poisson regression models used for analysis. Results 'Severe' 'Extremely Severe' anxiety prevalent sample. There significant differences depression based on age job role, older non-healthcare workers showing higher relative risks. Conclusions Our highlights burden patients, underscoring need targeted interventions, adults over 45 years old workers. Further research is needed better understand LC’s complex impacts develop effective clinical management strategies.

Language: Английский

---

An optimized data analytics pipeline for improving healthcare diagnosis using ensemble learning

Informatics in Medicine Unlocked, Journal Year: 2025, Volume and Issue: 53, P. 101623 - 101623

Published: Jan. 1, 2025

Language: Английский

---

Assessment of psychosocial aspects in adults in post-COVID-19 condition: the EURONET-SOMA recommendations on core outcome domains for clinical and research use

BMC Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 11, 2025

Abstract Background Harmonizing core outcome domains allows for pooling data, comparing interventions, and streamlining research evaluation. At the same time clinicians require concise feasible measures routine practice. Considering heterogeneity of post-COVID-19 condition, a biopsychosocial approach requires sufficient coverage psychosocial dimension with assessments. Previous recommendations sets have serious limitations regarding aspects condition. This paper specifically focuses on outcomes adults providing both comprehensive set streamlined clinical tailored use. Methods In structured Consensus Development Approach, European Network to improve diagnostic, treatment, healthcare patients persistent somatic symptoms (EURONET-SOMA) developed assessments The experts identified variables instruments which should be considered in studies suffering from are setting relevant research. Results We three higher-order dimensions each encompassing several domains: first dimension, “outcomes”, encompasses (1) classification/ diagnostics (2) (including fatigue), (3) psychopathological status mental comorbidities, (4) physical (5) neurocognitive symptoms, (6) illness consequences. second domain “mechanisms” (7) cognitive components, (8) affective (9) behavioral (10) social (11) psychobiological bridge markers (e.g., neuroimmunological psychoneuroendocrinological variables). third domain, “risk factors”, includes factors such as (12) socioeconomic sociocultural factors, (13) pre-existing health issues, (14) personality neuroticism), (15) adverse childhood experiences, (16) ongoing disability or pension claim, (17) media For specific suggested purposes Conclusions recommended help increase consistency condition across investigations, synergies, facilitate decision-making when different interventional approaches. It better identify subgroups heterogeneous populations offering practical tools practice through set.

Language: Английский

---

Cyclodextrin-Based Drug Delivery Systems for Depression: Improving Antidepressant Bioavailability and Targeted Central Nervous System Delivery

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 355 - 355

Published: March 10, 2025

Cyclodextrin (CD)-based drug delivery systems have emerged as a promising strategy to overcome limitations commonly encountered in antidepressant therapy, including low bioavailability, poor solubility, and suboptimal penetration of the blood–brain barrier. This review synthesizes current evidence demonstrating that complexing various classes antidepressants—such tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), atypical antidepressants—with β-CD or its derivatives significantly enhances solubility stability. In addition, encapsulation with CDs can diminish systemic toxicity improve pharmacokinetics, thereby helping optimize dosage regimens reduce adverse effects. Analysis published vitro vivo studies indicates CD formulations not only boost therapeutic efficacy but also enable sustained targeted release, which is critical for drugs requiring precise plasma tissue concentrations. When compared other carriers (e.g., liposomes, polymeric nanoparticles, dendrimers), CD-based often stand out their ease formulation, biocompatibility, cost-effectiveness, although limited drug-loading capacity be drawback. We recommend expanding trials substantiate clinical benefits CD–antidepressant complexes, particularly treatment-resistant cases specific subpopulations elderly pediatric patients). Additional investigations should explore hybrid systems—combining advanced nano- macroparticles—to amplify advantages address any limitations. Ultimately, integrating into holds substantial potential refine therapy outcomes, events, pave way more personalized, effective interventions depression.

Language: Английский

---

Temporal trends in prevalence for depressive disorders among women of childbearing age: Age-period-cohort analysis 2021

Journal of Affective Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---